As of Jun 19
| -0.16 / -3.13%|
The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 10.50, with a high estimate of 15.00 and a low estimate of 10.00. The median estimate represents a +111.69% increase from the last price of 4.96.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.